Search Results 891-900 of 14766 for anti-TNF drugs

  1. A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas - Mayo Clinic

    Drugs & Supplements A-Z · Health Books · Healthy ... A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas.

  2. Neomycin, Polymyxin B, And Hydrocortisone (Ophthalmic Route) Before Using - Mayo Clinic

    Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

  3. Atovaquone And Proguanil (Oral Route) Description and Brand Names - Mayo Clinic

    Antiprotozoals are medicines that are used to prevent and treat malaria, a red blood cell infection transmitted by the bite of a mosquito. This medicine is a ...

  4. Mayo Clinic researchers identify new strategies that may improve CAR-T cell therapy

    In other blood cancers, such as lymphoma and chronic lymphocytic leukemia, the response rates for treatment with CAR-T cell therapy remain low. To improve the ...

  5. Buprenorphine (Transdermal Route) Description and Brand Names - Mayo Clinic

    Buprenorphine skin patch is used to treat severe and persistent pain that requires an extended treatment period and when other pain medicines did not work well ...

  6. The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran) - Mayo Clinic

    The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been ...

  7. Trifarotene (Topical Application Route) Side Effects - Mayo Clinic

    Side Effects. Drug information provided by: Merative, Micromedex®. Along with its needed effects, a medicine may cause some unwanted effects. Although not ...

  8. A Study to Evaluate the Immune Response to Anti-HER2 Therapies - Mayo Clinic

    Scheded to start new anti=HER2 therapy/therapies. Provide written informed consent. Willingness to provide blood samples for correlative research purposes ...

  9. A Study to Evaluate the Patterns of Use of Biological Agents and Risk Factors for Discontinuation of Agents in Pediatric Crohn’s Disease (CD) and Ulcerative Colitis (UC) within the Pediatric Population - Mayo Clinic

    The study population for the remainder of the study will be all CD and UC patients in ICN who received their first biologic medication before 18 years of age ...

  10. Mayo Clinic Studying Genomics of Antiplatelet Heart Medication

    “This study will tell us whether this gene plays an important role in determining response to anti-platelet therapy after coronary interventions.” Michael ...